• Hello, please REGISTER and become a member of our community! You will then be able to start threads, post comments and send messages to other members. Thanks!

Testosterone Undecanoate - 250mg (Great cruise option/HRT)

Vision

Team supervisor P.S.L.
Staff member
Super Moderator
Joined
Aug 20, 2013
Messages
23,146
Reaction score
11,797
Points
113
Get Shredded!
Do you blast & cruise, or are you currently on HRT, how do you feel about weekly injections - is it getting old and tiresome, how about pinning a lot with your current cycle/blast? Have you considered ways to reduce building scar tissue?
Test Undeca is a great alterative to reduce all these above..
www.Euro-Pharmacies.net
[FONT=&quot]Well look no further!

[/FONT]
sPvOc6T.jpg


Look at this, what we have here we have Testosterone Undecanoate.

"Here at PSL we have all of your HRT/TRT needs covered, with a vast amount of Testosterone ester hormones"

www.PuritySourceLabs.ru

This shrouded compound is truly a contender in the compound arsenal with great reason, as TU can be utilized in a cruise, HRT or even a cycle stack where multi compounds are implemented.

Injections scheduling can be decreased with your testosterone in take, at the same time freeing up more injection sites/ for more volume with other compounds,
at the same time keeping you test levels up to par with injections as often as every 10-16 days (Half life of Test Undecanoate is 16 days)
Dosages may range from 250-500 weekly, or 500-1000, and the injections can be spaced out up until 10-14 days (or more)TU is used widely in many clinics world wide to treat men with hypogonadism, and HRT therapy..

The amazing benefits from this compound yields less injections, a much more stable blood environment, less fluctuations,
with the convenience of freeing up injection sites for other AAS compounds that may be needed in ones protocol..
This Test ester is very diverse, serving multi purposes!

Study below concerning TRT treatment with TU - Take your time reading it so you can absorb all the info, it can help with making a great choice by selecting TU as your NEW TRT compound.

Study #1

Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study.
Abstract


This paper reports the result of an open-label, non-randomized clinical trial investigating the efficacy and safety of an injectable preparation of testosterone undecanoate
(TU) dissolved in castor oil and given over a 3.2-year period.
In a previous study we demonstrated that injections of TU every 6 weeks resulted in satisfactory substitution but a tendency toward testosterone accumulation. Here we investigate prolonged TU treatment at
extended injection intervals in 7 hypogonadal men.
Injections were given at gradually increasing intervals between the fifth and 10th injection, and from then on every 12 weeks. Steady state kinetics were obtained after the 13th injection. Well-being, sexual activity,
clinical chemistry, prostate volume, and prostate-specific antigen (PSA) and serum hormone levels were monitored.
Patients were clinically well-adjusted throughout the study. Before the next injection, testosterone, dihydrotestosterone, and estradiol levels were mostly within the normal range and showed a
tendency to decrease with increasing injection intervals.
Body weight, hemoglobin, serum lipids, PSA, and prostate volume did not change significantly during the 3.2 years of treatment. PSA levels were always within the normal limit.
Maximal testosterone levels
during steady state kinetics were measured after 1 week with 32.0 +/- 11.7 nmol/L (mean +/- SD). Before the last injection, mean testosterone concentrations were 12.6 +/- 3.7 nmol/L. Compared with conventional
testosterone enanthate or cypionate treatment requiring injection intervals of 2-3 weeks and resulting in supraphysiological serum testosterone levels,
injections of TU at intervals of up to 3 months offer an excellent alternative for substitution therapy of male hypogonadism.

American Society of Andrology
Treatment of Male Hypogonadism With Testosterone
Undecanoate Injected at Extended Intervals of 12 Weeks: A
Phase II Study

SIGRID VON ECKARDSTEIN AND EBERHARD NIESCHLAG
From the Institute of Reproductive Medicine of the University, D-48129 Munster, Germany


Testosterone preparations have been in clinical use for
substitution of male hypogonadism for more than a
half century. However, only within recent years has the
choice of different delivery forms increased. The newly
developed transdermal preparations having short half-
lives are predominantly tailored for therapy of senescent
men (Nieschlag, 1998). For substitution of younger hy-
pogonadal men and for hormonal male contraception,
long-acting substances are more desirable. Therefore, the
development and first clinical uses of injectable testoster-
one buciclate (Behre et al, 1995) and testosterone unde-
canoate (TU; Partsch et al, 1995; Zhang et al, 1998; Behre
et al, 1999a) attracted much attention.
Six-week injections of 1000 mg TU in 4 mL castor oil
resulted in well-maintained androgen-dependent functions
without serious side effects (Nieschlag et al, 1999). How-
ever, after 4 injections, a tendency toward a gradual in-
crease in testosterone levels was observed, suggesting that
prolongation of application intervals should be possible.

In the present paper we report the results of continued
substitution therapy with TU in 7 hypogonadal men, and
explore the efficacy and safety of injection intervals of
up to 12 weeks, for a total period of 3.2 years.

Materials and Methods
Patients

Seven men with primary or secondary hypogonadism aged 20
to 57 years, who had already participated in the first trial with
6-week injections of TU agreed to receive continuing treatment.
Inclusion and exclusion criteria to enroll patients for TU treat-
ment have been described previously (Nieschlag et al, 1999).
Prolongation of the initial study protocol was approved by the
ethics committee of the university and the State Medical Board,
Munster. Written informed consent was obtained from subjects.
Rules for clinical studies as provided by the Declaration of Hel-
sinki and the standards of good clinical practice were followed.
Five patients entering the follow-up phase had primary hy-
pogonadism, and 2 had secondary hypogonadism. The limit of
serum testosterone for establishing the diagnosis of hypogonad-
ism in our institute is 12 nmol/L. Diagnosis and the previous
mode of substitution are given in Table 1. Two men had previ-
ously participated in the initial study comparing the pharmaco-
kinetics of TU dissolved in either tea seed (‘‘Chinese prepara-
tion’’) or castor oil (Behre et al, 1999a)
www.PuritySourceLabs.ru Test Undecanoate


May/June 2002
Table 1.
Clinical characteristics of patients entering the follow-up phase of substitution therapy with 1000 mg TU
Patient Diagnosis Age (y)† Treatment (before TU)†

1 Bilateral orchidectomy due to seminoma 37 TE 250 mg/4 weeks
2 Bilateral testicular atrophy due to cryptorchidism 19 None
3 Bilateral orchidectomy due to seminoma age 49 TE 250 mg/3 to 4 weeks
4 Bilateral orchidectomy due to seminoma age 37 None
5 Bilateral orchidectomy due to seminoma age 57 TE 250 mg/3 to 4 weeks
6 Bilateral orchidectomy due to seminoma age 31 TE 250 mg/2 to 4 weeks

7 Hypogonadotropic hypogonadism (ectopic neurohypophysis age 29 TE 250 mg/4 weeksJournal of Andrology

* Patients who had already participated in the study on comparative pharmacokinetics with TU in castor oil or tea seed oil.
† Age and previous treatment modalities refer to the date before the first TU application. TE indicates testosterone enanthate


Testosterone Preparation

TU was obtained from Jenapharm GmbH & Co. KG, Jena, Ger-
many. Each ampule contained 1000 mg TU dissolved in 4 ml
castor oil. Single injections were administered with the total vol-
ume at one site intramuscularly into the musculus gluteus med-
ius, taking care to perform injections slowly to avoid pain.

Study Design

The study was a clinical, open label, nonrandomized trial.
Screening examinations had been completed before the first in-
jection with TU as described previously (Nieschlag et al, 1999).
Before the first TU application, all men under current treatment
completed a washout phase of at least 4 weeks. An overview of
studies evaluating TU, including the current design, is given in
Table 2. Before entering the follow-up phase, all patients under-
went another complete physical and genital investigation and
assessment of clinical chemistry, hematology, and lipids, as well
as sonography of testes and prostate. Well-being and sexuality
were investigated by standardized questionnaires immediately
before and at half-time between TU injections. Before each ap-
plication, blood samples for measurements of hormones, sex
hormone binding globulin (SHBG), albumin, PSA, clinical
chemistry, lipidology, and hematology were obtained. Prostate
size was determined sonographically before every second injec-tion.

After 4 injections had been given at 6-week intervals, the
intervals were gradually extended between the 5th and 10th in-
jections. Intervals were extended by 1 to 2 weeks if serum tes-
tosterone levels were above 12 nmol/L before the next injection,
and if subjective impairment of well-being was absent. From the
10th injection onward, TU was applied every 12 weeks. After
the 13th application, steady state kinetics were obtained as evi-
denced by weekly determinations of testosterone serum concen-
trations for 12 weeks. Six weeks after the 18th application, the
study was finished with a detailed final investigation, including
a physical and genital examination, sonography of prostate and
scrotal contents, and all blood values that had been monitoredduring the study.
www.PuritySourceLabs.ru Testosterone Undecanoate
Hormone Assays

Analysis was performed from venous blood samples that were
centrifuged at 800
3g
for 10 minutes and then stored at
220
8C
until measurements were performed at the end of the study. Care
was taken so that samples of one subject were measured withinone assay.

Serum concentrations of follicle-stimulating hormone (FSH),
luteinizing hormone (LH), estradiol, SHBG, prolactin, and PSA
were analyzed by highly specific time-resolved immunofluoro-
metric assays (Autodelfia; Wallac, Freiburg, Germany). The low-
er detection limits were 0.12 IU/L and 0.25 IU/L for FSH and
LH, respectively; and 25 pmol/L, 6.3 nmol/L, and 0.5mg/L for
estradiol, SHBG, and PSA, respectively. The normal range in
our laboratory is 1–7 IU/L and 2–10 IU/L for FSH and LH,
respectively, and 11–71 nmol/L for SHBG. The upper limits of
normal for estradiol and PSA are 250 pmol/L and 4m
g/L,
respectively. The intraassay and interassay coefficients of variation
were 0.5 and 1.9 for FSH, 1.7 and 2.2 for LH, 1.9 and 5.0 for
estradiol, 1.0 and 7.2 for SHBG, and 3.4 and 4.9 for PSA. Serum
testosterone was measured by an enzyme-linked immunosorbent
assay (Biocam Immunosystems; DRG Instruments, Marburg,
Germany). The lower limit of normal is 12 nmol/L. Dihydrotes-
tosterone (DHT) was analyzed by radioimmunoassay (DSL
9600; Diagnostic System Laboratories, Sinsheim, Germany). In-
traassay and interassay coefficients of variation for testosterone
and DHT were 3.4 and 5.6, and 4.8 and 9.2, respectively. Free-
testosterone was calculated using the formula suggested by Ver-
meulen et al (1999)
Eckardstein and Nieschlag ·
Injectable Testosterone Undecanoate

Clinical Chemistry, Hematology, and Lipids
Biochemical and hematological parameters were determined at
the Institute of Laboratory Medicine, University of Mu
̈ nster us-
ing, standard techniques. Quality control was performed accord-
ing to the standards provided by the German Society of Clinical
Chemistry.
Evaluation of Well-Being and Sexuality
During treatment patients were asked to complete standardized
questionnaires to assess mood and sexual performance. Com-
pleted questionnaires were obtained before injections and at the
halfway point of the respective injection interval.
Evaluation of Prostate
Prostate volume was monitored by transrectal ultrasound using
a 7.5 MHz probe (The Panther; B&K Medical, Norderstedt, Ger-
many). Prostate examinations included planimetric determination
of volume (Behre et al, 2000) and assessment of sonographic
texture.
Statistics
Statistical analysis was performed using the SPSS statistical
package for Windows (version 10.0). All variables were checked
for normal distribution by the Kolmogorov-Smirnov one-sample
test for goodness-of-fit. Descriptive statistics are given as either
means
6
SD or median, and the 2.5 to 97.5 percentiles. For
analysis of variance (ANOVA) over time, one-way analysis of
variance was calculated, which was followed by the Dunnett
post-hoc test for intergroup comparison if an overall level of
significance of P

.05 was reached. When necessary, analysis
was performed after logarithmic transformation of data.

Results

General Effects, Well-Being, and Sexual Function
During TU applications, patients reported stable values
for all parameters of well-being and sexual function
(numbers of erections and ejaculations per week and sat-
isfaction with sex life). At the end of the injection inter-
val, when questionnaires were compared with those at
half-time, no statistically significant differences werefound.

Injections were well tolerated by all men except one,
who requested extremely slow injections to avoid discom-
fort. No local side effects or impaired well-being oc-
curred, except for one occasion when, during prostate so-
nography, a patient had short-term circulatory problems
after the injection. One patient complained initially of
mild acne within 2 weeks following injection. However,
these problems disappeared during the 12-week intervals.
In addition, the same patient developed slight gyneco-
mastia during the first part of the study (6 weekly injec-
tions), which remained unchanged during the follow-up
period.

General adverse events related to the treatment were
not observed. One patient experienced an episode of her-
pes zoster, which required antiviral therapy after severe
psychological trauma.
Body Weight
During TU applications, body weight increased slightly
from 83.5
6
9.5 kg to 85.7
6
9.1 kg without reaching
the level for statistical significance. Compared with the
baseline, the maximum mean body weight was observed
at the end of the study period.
Testosterone and Free Testosterone
Testosterone serum levels and calculated free testosterone
levels obtained before injections are shown in Figure 1.
During the 6-week injection interval, testosterone levels
increased initially from 5.2
6
3.1 nmol/L to 23.8
6
7.8
nmol/L after patients had received 4 injections in 6 weeks.
With extended injection intervals, preapplication testos-
terone levels decreased and were just at the lower limit
of normal, with 12.6
6
3.7 nmol/L before the last injec-
tion. A comparable pattern was observed for calculated
free testosterone levels, which rose to 573
6
202 pmol/
L after the 6-week period, and then returned to the lower
limit of normal (291
6
93 pmol/L) after 8 injections had
been performed at 12-week intervals.
Maximum steady state kinetics for levels of testoster-
one and free testosterone were reached after 1 week. The
mean maximum concentration for testosterone was 32
nmol/L, ranging from a minimum of 15.6 to a maximum
of 44.3 nmol/L. A comparable pattern was observed for
free testosterone levels, with a mean of 787 pmol/L (Table
3). Initial kinetics obtained in 14 subjects after the first
injection of TU and steady state kinetics in the current
trial are shown in Figure 2.
Estradiol and DHT
DHT and estradiol concentrations essentially followed the
pattern of that for testosterone and free testosterone. Dur-
ing the short injection intervals, DHT levels occasionally
exceeded the upper normal limit but returned to the lower
limit of normal after 5 injections over 12 weeks had been
applied (Figure 1). Estradiol levels always stayed within
normal limits.
LH and FSH
LH and FSH values decreased significantly during the
study, from initial values of 18.7
7.1 IU/L (LH) and 30.5,
27.3 IU/L (FSH) to 0.4,
0.8 IU/L (LH) and 1.5,
2.9 IU/L (FSH) after 24 weeks. Before the last injec-
tion, LH values of 3.0,
5.0 IU/L and FSH values of 7.7,
13.9 IU/L were measured

www.PuritySourceLabs.ru

Test Undecanoate
PSL
 
Last edited:

ldog

Pain is Pleasure
Board Rep
Joined
Nov 8, 2014
Messages
13,310
Reaction score
4,392
Points
113
This is a great option V. I've played around with Andriol before and had limited success. For any guys on TRT, this injectible Test Undecnoate offer is a great opportunity to take your TRT to a new level. I may have to try some for myself!
 
Last edited:

jacKs4

Registered Member
Joined
May 29, 2015
Messages
75
Reaction score
3
Points
8
What is the recommended way to go from Test E 2x weekly 250mg to TU to maintain blood levels.
 

Vision

Team supervisor P.S.L.
Staff member
Super Moderator
Joined
Aug 20, 2013
Messages
23,146
Reaction score
11,797
Points
113
It's almost cruising season, summer is coming to an end...Stock up on one of the most underrated compounds for your cruising needs!
 

VTX

Registered Member
Joined
Sep 17, 2015
Messages
988
Reaction score
26
Points
28
Would this be a good option for a women as TRT. Vision what type of carrier oils do y'all use. I would like to be able to use a slin for my wife's injection. Don't think a larger gauge is going to be an option. I have plenty pharmaceutical grade from the doctor that is in grapeseed oil. It's a test cyp but it's thick
 

Vision

Team supervisor P.S.L.
Staff member
Super Moderator
Joined
Aug 20, 2013
Messages
23,146
Reaction score
11,797
Points
113
Would this be a good option for a women as TRT. Vision what type of carrier oils do y'all use. I would like to be able to use a slin for my wife's injection. Don't think a larger gauge is going to be an option. I have plenty pharmaceutical grade from the doctor that is in grapeseed oil. It's a test cyp but it's thick

EP uses a complete pharmaceutical grade 100% "SYNTHETIC" Hypoalergic crystal clear oil...None food derivative...It's smooth and painless with zero impurities (this makes it virtually infection/contamination proof) when it concerns the carry/transport oil... Many people use smaller gauges with great success...

This is a GREAT option for almost anyone for TRT, but of course seeing blood work would be necessary before I made any suggestions...Because individuals will vary with metabolization and such,protocols and so on!
 

VTX

Registered Member
Joined
Sep 17, 2015
Messages
988
Reaction score
26
Points
28
Yes understand completely. Have been talking with Sheriv and my wife will be doing a female hormone optimization checkup. She has to wait 17 more days as this will be the optimal time for her to do bloods. She 48 and starting to feel some midlife issues. Once the blood work is in we can go from there as far as dosage is concerned.
 

DsEq194

Registered Member
Joined
Sep 2, 2016
Messages
879
Reaction score
14
Points
18
Vision, bro.... that is an awesome deal, didn't know you guys had test u. This ship from domestic or is it import only?

Sent from my SM-G930T using Tapatalk
 

Pushtoday

Board Rep
Joined
May 17, 2016
Messages
2,381
Reaction score
269
Points
83
Just ONE pin a week.

Testosterone Undecanoate - 250mg/ml 10ml/vial EP
testosterone-undecanoate-250mgml-10mlvial-ep.jpg

Supplier:Euro-Pharmacies
Chemical Name:Testosterone Undecanoate
Comes In: 10ml vial -250 mg/ml
Dosage: 500-1200mg per week
Active time: Approx 15-17 days
Class:Anabolic/Androgenic Steroid

Cruise dose 250mg a week.

Stack everything else on top.
TREN
MAST
DECA
DBOL
DROL
Anything...

ONE PIN A WEEK!
http://puritysourcelabs.ru/injectable/530-testosterone-undecanoate-250mgml-10mlvial-ep.html


 

Vision

Team supervisor P.S.L.
Staff member
Super Moderator
Joined
Aug 20, 2013
Messages
23,146
Reaction score
11,797
Points
113
Just ONE pin a week.

Testosterone Undecanoate - 250mg/ml 10ml/vial EP
View attachment 38506

Supplier:Euro-Pharmacies
Chemical Name:Testosterone Undecanoate
Comes In: 10ml vial -250 mg/ml
Dosage: 500-1200mg per week
Active time: Approx 15-17 days
Class:Anabolic/Androgenic Steroid

Cruise dose 250mg a week.

Stack everything else on top.
TREN
MAST
DECA
DBOL
DROL
Anything...

ONE PIN A WEEK!
http://puritysourcelabs.ru/injectable/530-testosterone-undecanoate-250mgml-10mlvial-ep.html



Absolutely stellar feedback man..
 

maxmuscle1

Registered User
Registered Member
Joined
Apr 4, 2015
Messages
23,168
Reaction score
17,982
Points
113
I’d like to mix this with Nandrolone Laurate(Laurabolin) for TRT!

Max


Sent from my iPhone using Tapatalk
 

Jswole220

Registered Member
Joined
Dec 20, 2017
Messages
5,359
Reaction score
2,090
Points
113
Location
Earth ��
I’d like to mix this with Nandrolone Laurate(Laurabolin) for TRT!

Max


Sent from my iPhone using Tapatalk
I thought about using TU for trt or cruise but I don’t mind pinning and think Test e and cyp are better options. Next cruise I’ll be using iso 😃. Did I ever tell you how much I like test iso? Lol waiting for that other guy to start his sale so I can stock ^
 

HFO3

NO LIMITS.
Staff member
Super Moderator
Joined
Feb 22, 2013
Messages
12,516
Reaction score
8,783
Points
113
1 pin a week would be a nice change


Sent from my iPhone using Tapatalk
 

maxmuscle1

Registered User
Registered Member
Joined
Apr 4, 2015
Messages
23,168
Reaction score
17,982
Points
113
I thought about using TU for trt or cruise but I don’t mind pinning and think Test e and cyp are better options. Next cruise I’ll be using iso . Did I ever tell you how much I like test iso? Lol waiting for that other guy to start his sale so I can stock ^

I don’t know what the hold up is over there!?
If I did use TU, I would probably do 2ml every 2 weeks otherwise I couldn’t see the point of using it. It would be nice to only have to pin twice a month if it worked well. I’m in TRT for life so it would be convenient.

Max


Sent from my iPhone using Tapatalk
 

Jswole220

Registered Member
Joined
Dec 20, 2017
Messages
5,359
Reaction score
2,090
Points
113
Location
Earth ��
I don’t know what the hold up is over there!?
If I did use TU, I would probably do 2ml every 2 weeks otherwise I couldn’t see the point of using it. It would be nice to only have to pin twice a month if it worked well. I’m in TRT for life so it would be convenient.

Max


Sent from my iPhone using Tapatalk
I’m in the same boat as you brother pct is not for me lol thoes days are long gone. I will say I do want to get a vial or two of this from psl for when I have to take long trips and gear is not an option to bring. I think it could definitely come in handy in a situation like that
 

maxmuscle1

Registered User
Registered Member
Joined
Apr 4, 2015
Messages
23,168
Reaction score
17,982
Points
113
I’m in the same boat as you brother pct is not for me lol thoes days are long gone. I will say I do want to get a vial or two of this from psl for when I have to take long trips and gear is not an option to bring. I think it could definitely come in handy in a situation like that

Mos Def!


Sent from my iPhone using Tapatalk
 

ilfirin

Registered Member
Joined
Sep 2, 2019
Messages
222
Reaction score
67
Points
28
Been awhile since I ordered from PSL, I guess I have just been turned on by local sources. This is very enticing though... Would be great to switch over to undecanoate in the months before my cruise. Stable blood levels on vacation and don't have to worry about getting caught with anything. I also wonder though, like a previous person asked, what is the best way to switch to this from cyp or enan without throwing everything out of whack?
 

Vision

Team supervisor P.S.L.
Staff member
Super Moderator
Joined
Aug 20, 2013
Messages
23,146
Reaction score
11,797
Points
113
Been awhile since I ordered from PSL, I guess I have just been turned on by local sources. This is very enticing though... Would be great to switch over to undecanoate in the months before my cruise. Stable blood levels on vacation and don't have to worry about getting caught with anything. I also wonder though, like a previous person asked, what is the best way to switch to this from cyp or enan without throwing everything out of whack?

The best way to switch over is to incorporate whatever Ester you wish cyp/Enan, and I would begin running it at least two or three weeks prior to stopping the other.. 3 weeks is about good..
 

Pushtoday

Board Rep
Joined
May 17, 2016
Messages
2,381
Reaction score
269
Points
83
This has to be one of my favorite test esters.
1cc a week or even every ten days for a cruise.
2cc a week for some long layered test levels.

e1ee2b96e867e47cdb7e38cbb5d17197.jpg


I get them from:
https://puritysourcelabs.ru/


Sent from my iPhone using Tapatalk
 

Vision

Team supervisor P.S.L.
Staff member
Super Moderator
Joined
Aug 20, 2013
Messages
23,146
Reaction score
11,797
Points
113
Well hello there, undeca :) I'll be seeing you soon

Sent from my XT1650 using Tapatalk

There's quite a few of us that are looking at this test ester... This with some sarms YK11 sounds like a nice cruise



Available locally in your neighborhood




YK11 is a SARM and myostatin inhibitor in one

Japanese researchers are doing tests with a new SARM , which according to the first publications has a stronger anabolic effect than a classic anabolic steroid such as DHT. YK11 attaches itself to the androgen receptor, produces few androgenic effects and inhibits - in a way that the researchers do not understand - the effect of myostatin
You can see YK11 above. If you click on the picture, a larger version will appear. It is a strange molecule that cheerful chemists probably once made while enjoying home-brewed ethanol, and then forgot. The Japanese found him when they screened compounds for androgenic properties. The whole thing is called (17-alpha, 20E) 17.20 - [(1-methoxyethylidene) bis (oxy)] 3-oxo-19-norpregna-4,20-diene 21-carboxylic acid methyl ester .
PubMed only has two studies into YK11. [PubMed: YK11] The researchers get their money from a prestigious government fund for young up-and-coming talent. If you get money from such an institution, you are not going to suffice with two publications, but you will be helping a whole mountain of publications into the world. We will hear more about YK11 soon.
In 2011, Yuichiro Kanno of Toho University published a first study on YK11, in which he demonstrated that the brand value connection was a SARM. YK11 attaches itself to the androgen receptor, but initiates in cells only to a limited extent the processes that can lead to the classical side effects of androgens, such as the growth of body hair, the increase of the aggression and growth of the prostate.
Most SARMs have relatively few androgenic side effects, but often - if you compare it with a substance such as testosterone - relatively little anabolic effect. At YK11 that may be different, Yuichiro Kanno reported in 2013 in Biological and Pharmaceutical Bulletin.

In that research, Kanno experimented with C2C12 muscle cells, and not with test animals or humans. Nevertheless, Biological and Pharmaceutical Bulletin found Kanno's article valuable enough to bomb it into a " Highlighted Paper selected by Editor-in-Chief ". That's no wonder. Kanno discovered that muscle cells produce more anabolic factors if you expose them to 500 nanomoles of YK11 than if you expose those same muscle cells to 500 nanomoles of DHT.
yk11sarm2.gif

And take a look. YK11 provides a greater increase in the production of Myf5, MyoD and myogenin than DHT. Myf5, MyoD and myogenin are signal proteins that make muscles grow.

The figure below shows how that is possible. YK11 makes muscle cells produce more follistatin - considerably more than DHT. Follistatin is a strong myostatin inhibitor.
yk11sarm.gif


yk11sarm3.gif


If the researchers switched off the androgen receptor, YK11 lost its anabolic effect. YK11 therefore works via the androgen receptor. If the researchers switched off follistatin, the anabolic effect also disappeared. Proof supplied: YK11 is a SARM and a myostatin inhibitor .
Good old testosterone also stimulates the production of follistatin. [Endocrinology. 2009 Mar; 150 (3): 1259-68.] Maybe with YK11 we have a substance in our hands that is just as good a muscle enhancer as testosterone, but without the side effects.
" YK11 was shown to be an appropriate anabolic SARM, " the researchers write. " However, further investigation is required to elucidate the mechanisms of the differential activation of the follistatin pathway by YK11 and DHT ."

Regulation of myogenic differentiation by androgens: cross talk between androgen receptor/ beta-catenin and follistatin/transforming growth factor-beta signaling pathways.

Singh R1, Bhasin S, Braga M, Artaza JN, Pervin S, Taylor WE, Krishnan V, Sinha SK, Rajavashisth TB, Jasuja R.
Author information

1Division of Endocrinology and Research Centers in Minority Institutions Core Laboratory, Charles Drew University of Medicine and Science, Los Angeles, California 90059, USA. rajansingh@mednet.ucla.edu

Abstract

Androgens are important regulators of body composition and promote myogenic differentiation and inhibit adipogenesis of mesenchymal, multipotent cells. Here, we investigated the mechanisms by which androgens induce myogenic differentiation of mesenchymal multipotent cells. Incubation of mesenchymal multipotent C3H 10T1/2 cells with testosterone and dihydrotestosterone promoted nuclear translocation of androgen receptor (AR)/beta-catenin complex and physical interaction of AR, beta-catenin, and T-cell factor-4 (TCF-4). Inhibition of beta-catenin by small inhibitory RNAs significantly decreased testosterone-induced stimulation of myogenic differentiation. Overexpression of TCF-4, a molecule downstream of beta-catenin in Wnt signaling cascade, in C3H 10T1/2 cells significantly up-regulated expression of myoD and myosin heavy chain II proteins and of follistatin (Fst), which binds and antagonizes native ligands of the TGF-beta/Smad pathway. Gene array analysis of C3H 10T1/2 cells treated with testosterone revealed that testosterone up-regulated the expression of Fst and modified the expression of several signaling molecules involved in the TGF-beta/Smad pathway, including Smad7. Lowering of testosterone levels in mice by orchidectomy led to a significant decrease in Fst and Smad7 expression; conversely, testosterone supplementation in castrated mice up-regulated Fst and Smad7 mRNA expression in androgen-responsive levator ani muscle. Testosterone-induced up-regulation of MyoD and myosin heavy chain II proteins in C3H 10T1/2 cells was abolished in cells simultaneously treated with anti-Fst antibody, suggesting an essential role of Fst during testosterone regulation of myogenic differentiation. In conclusion, our data suggest the involvement of AR, beta-catenin, and TCF-4 pathway during androgen action to activate a number of Wnt target genes, including Fst, and cross communication with the Smad signaling pathway.

PMID: 18948405 PMCID: PMC2654730 DOI: 10.1210/en.2008-0858

Selective androgen receptor modulator, YK11, regulates myogenic differentiation of C2C12 myoblasts by follistatin expression.

Kanno Y1, Ota R, Someya K, Kusakabe T, Kato K, Inouye Y.
Author information

1Faculty of Pharmaceutical Sciences, Toho University.

Abstract

The myogenic differentiation of C2C12 myoblast cells is induced by the novel androgen receptor (AR) partial agonist, (17α,20E)-17,20-[(1-methoxyethylidene)bis-(oxy)]-3-oxo-19-norpregna-4,20-diene-21-carboxylic acid methyl ester (YK11), as well as by dihydrotestosterone (DHT). YK11 is a selective androgen receptor modulator (SARM), which activates AR without the N/C interaction. In this study, we further investigated the mechanism by which YK11 induces myogenic differentiation of C2C12 cells. The induction of key myogenic regulatory factors (MRFs), such as myogenic differentiation factor (MyoD), myogenic factor 5 (Myf5) and myogenin, was more significant in the presence of YK11 than in the presence of DHT. YK11 treatment of C2C12 cells, but not DHT, induced the expression of follistatin (Fst), and the YK11-mediated myogenic differentiation was reversed by anti-Fst antibody. These results suggest that the induction of Fst is important for the anabolic effect of YK11.
 

HFO3

NO LIMITS.
Staff member
Super Moderator
Joined
Feb 22, 2013
Messages
12,516
Reaction score
8,783
Points
113
21.jpg


I know many of you guys know this but for those who don’t, here's some good intel on what your'e actually receiving per 100 mgs of test on 5 different esters. I think the only one missing is Isocaproate.

Deca and NPP are the bottom two listed
 
Top